So far, only a stapled peptide therapeutic, ALRN-6924, inhibiting  both MDM2 and MDMX [30] has been developed and is currently in Phase I clinical trial in wild-type p53 AML and MDS (clinical trial ID: NCT02909972). Here, MDM2 is linked to myelodysplastic syndrome.